SCHEMBL5543917

SCHEMBL5543917

CCOC(=O)CCc1ccc([O])cc1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.74
CYP4A11 Q02928 2/20 0.74
CYP4Z1 Q86W10 3/20 0.57
TDP1 Q9NUW8 1/20 0.52
HRH3 Q9Y5N1 1/20 0.49
ABCB1 P08183 1/20 0.48
CYP4F11 Q9HBI6 1/20 0.48
CYP4F12 Q9HCS2 1/20 0.48
EPHX2 P34913 1/20 0.46
ALOX5 P09917 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
P2RY12 Q9H244 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68902 0.92 CYP4F2 (0.85) CYP4F2CYP4A11CYP4Z1TDP1HRH3
SCHEMBL5545806 0.89 CYP4F2 (0.60) CYP4F2CYP4A11CYP4Z1TDP1ABCB1
SCHEMBL5542104 0.88 CYP4Z1 (0.60) CYP4F2CYP4A11CYP4Z1TDP1CYP4F11
SCHEMBL363982 0.87 CYP4F2 (0.77) CYP4F2CYP4A11CYP4Z1TDP1HRH3
SCHEMBL11437256 0.87 CYP4F2 (0.77) CYP4F2CYP4A11CYP4Z1TDP1HRH3
SCHEMBL879130 0.87 CYP4F2 (0.77) CYP4F2CYP4A11CYP4Z1TDP1HRH3
SCHEMBL10206072 0.87 CYP4F2 (0.77) CYP4F2CYP4A11CYP4Z1TDP1HRH3
SCHEMBL5545484 0.86 CYP4Z1 (0.59) CYP4F2CYP4A11CYP4Z1TDP1CYP4F11
SCHEMBL5544351 0.86 CYP4Z1 (0.59) CYP4F2CYP4A11CYP4Z1TDP1CYP4F11
SCHEMBL4889211 0.85 CYP4F2 (0.80) CYP4F2CYP4A11CYP4Z1TDP1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-4098816-A HYPOGLYCEMIC AGENTS AND ANTILIPEMIC AGENTS BEECHAM GROUP LIMITED (GB) 1978-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP4F2 954/4885CYP4A11 1804/4885CYP4Z1 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.